指南与共识外周动脉疾病

血脂管理指南依从性与CLTI血运重建后死亡及肢体事件降低相关

Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia.
指南 / 共识 · J Vasc Surg · 2017-05-12

该研究纳入2005至2014年在单中心因慢性威胁肢体缺血(CLTI)首次血运重建的931例患者(1019条肢体),评估出院时他汀强度与2013年ACC/AHA指南推荐的一致性。仅35%患者使用推荐强度他汀,出院时使用推荐强度他汀与全因死亡(HR 0.73)和主要不良肢体事件(MALE,HR 0.71)风险降低独立相关。

要点

  • CLTI血运重建后仅35%患者使用指南推荐强度他汀,≤75岁者仅20%。
  • 出院使用推荐强度他汀与死亡(HR 0.73)和MALE(HR 0.71)风险降低相关。
  • >75岁与≤75岁患者获益相似,指南依从性可作为质量改进靶点。

核心结论

  • 遵循2013年ACC/AHA血脂指南推荐强度使用他汀与CLTI血运重建后生存改善和MALE率降低显著相关。

研究设计与样本

  • 回顾性队列研究,纳入Beth Israel Deaconess Medical Center 2005至2014年因CLTI首次血运重建的患者。
  • 排除血液透析患者252例后,分析931例患者的1019条肢体,中位随访380天。
  • 按术后他汀强度分为高、中、低强度或无他汀,采用倾向评分及Cox回归校正混杂因素。

主要发现

  • 总体仅35%患者使用推荐强度他汀,>75岁者55%,≤75岁者20%。
  • 出院使用任何他汀与较低死亡风险相关(HR 0.71;95%CI 0.60-0.90;P<.01)。
  • 出院使用推荐强度他汀与较低死亡风险(HR 0.73;95%CI 0.60-0.99;P<.05)和较低MALE率(HR 0.71;95%CI 0.51-0.97;P<.05)相关。
  • >75岁与≤75岁患者获益相似;>75岁患者中中等强度他汀较高强度他汀死亡和MALE率更低但无统计学显著性。

关键数值与推荐

  • 2013年ACC/AHA指南推荐:所有≤75岁CLTI患者使用高强度他汀。
  • >75岁无禁忌或未透析的CLTI患者推荐中等强度他汀。

临床怎么用

  • CLTI血运重建后应评估他汀使用强度是否符合指南推荐,尤其关注≤75岁患者。
  • 提高指南推荐强度他汀的依从性可作为改善预后的质量改进措施。

局限性

  • 回顾性单中心研究,存在选择偏倚和未测量混杂可能。
  • 排除血液透析患者,结论不适用于该人群。
  • 中位随访380天,长期获益未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The 2013 American College of Cardiology/American Heart Association lipid management guidelines recommend high-intensity statins for all patients ≤75 years old with chronic limb-threatening ischemia (CLTI) and moderate-intensity statins for CLTI patients >75 years old without contraindications or on dialysis, but these recommendations are based primarily on coronary and stroke data. We aimed to validate these guidelines in patients with CLTI and to assess current adherence to these recommendations. METHODS: We identified all patients with CLTI who underwent first-time revascularization (endovascular or surgical) at Beth Israel Deaconess Medical Center from 2005 to 2014. Patients were classified as taking high-intensity, moderate-intensity, low-intensity, or no statin postoperatively. Outcomes included death and major adverse limb event (MALE). Propensity scores were calculated for the probability of receiving guideline-recommended intensity of statin therapy to account for nonrandom assignment of treatments. Cox regression models were constructed and adjusted for the propensity scores and further adjusted for strong potential confounders. RESULTS: After excluding patients on hemodialysis (n = 252), we identified 1019 limbs from 931 patients with a median follow-up of 380 days. Patients discharged on the recommended statin intensity had higher rates of preoperative statin use, coronary artery disease, chronic kidney disease, stroke, atrial fibrillation, congestive heart failure, and coronary artery bypass grafting; they had lower smoking rates and were less likely to be ambulatory preoperatively. Overall, only 35% were taking the recommended statin dosage: 55% of those >75 years old and 20% of those ≤75 years old. In multivariable analysis including propensity scores where appropriate, discharge on any statin was associated with lower mortality (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.60-0.90; P < .01). Discharge on the recommended intensity of statin therapy was associated with lower mortality (HR, 0.73; 95% CI, 0.60-0.99; P < .05) and lower MALE rate (HR, 0.71; 95% CI, 0.51-0.97; P < .05). Patients >75 years old and ≤75 years old accrued similar benefit. In patients >75 years old, moderate-intensity statin therapy was associated with lower rates of death and MALE compared with high-intensity therapy but did not reach statistical significance. CONCLUSIONS: Use of the recommended intensity of statin therapy in compliance with 2013 American College of Cardiology/American Heart Association lipid management guidelines is associated with significantly improved survival and lower MALE rate in patients undergoing revascularization for CLTI. Adherence to current guidelines is an appealing target for quality improvement.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Deery SE, Darling JD, et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2017. PMID: 28506476. doi:10.1016/j.jvs.2017.03.416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。